Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
about
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancerTargeted therapies and immunotherapy in non-small-cell lung cancerCurrent Status and Development of Traditional Chemotherapy in Non-small Cell Lung Cancer under the Background of Targeted TherapyProgress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancerThe Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-AnalysisClinical experiences with molecular targeted therapy in lung cancer in ChinaOptimal therapeutic strategy for non-small cell lung cancer with mutated epidermal growth factor receptorMethodology of health-related quality of life analysis in phase III advanced non-small-cell lung cancer clinical trials: a critical reviewUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsNext-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidenceAfatinib for the treatment of metastatic non-small cell lung cancerRisk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdatePhase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.UGT genotyping in belinostat dosingTargeted drugs for unselected patients with advanced non-small-cell lung cancer: a network meta-analysisThe efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).Molecular pathways and therapeutic targets in lung cancerRandomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerA phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidenceEpidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysisGefitinib-Integrated Regimen versus Chemotherapy Alone in Heavily Pretreated Patients with Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Case-Control StudyChinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).Emerging treatment for advanced lung cancer with EGFR mutation.Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutationsSequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanismEGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionEfficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinomaThe effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis.Personalized maintenance therapy in advanced non-small cell lung cancer.Clinical trials for lung cancer in ChinaChemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.The Value of MicroRNA-155 as a Prognostic Factor for Survival in Non-Small Cell Lung Cancer: A Meta-Analysis.Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocMolecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
P2860
Q26471909-50B99ED9-C23F-4DFC-9C41-0B939667AF9DQ26738986-F1BBDD79-BA2B-4361-9CD5-B23885E8278EQ26783432-D0F7CC1C-AF46-479B-BBF9-9977AF7A3215Q26784298-45F700CB-B77C-4ABE-9B94-E87D3CAA5772Q26786142-78A0E1C7-7163-4F26-A009-D52AE8D54524Q26798228-E9630129-B1CB-4124-8C59-B40D34603348Q26859993-9A5E28FB-8582-4205-B781-5AABC1B46437Q28068435-AC31EDD5-6958-471D-826E-443A27C38572Q28075291-6D648D64-D005-46AB-AA49-A3EB0BABD7D9Q28079320-99AF421E-77EA-419C-8492-D774AB9DC2B4Q28082181-92138C5A-24C6-4853-AEF5-764BB990103BQ30248499-9F47E8C3-C76E-406D-84E3-FC337EEE32E6Q30356434-A566878A-2BA7-4BE8-92A9-FDD7F654AAB3Q33419961-B6F719BA-E61E-4DD7-AECA-CD65E29083B5Q33429235-94331D55-B4F6-46D2-A2D3-8848EC2A0FABQ33430200-92A8AFBD-CC18-4E4A-875A-119749CD9E0DQ33437650-351F394B-18C0-40B4-951B-F5F307104680Q33688872-C9796E05-294E-4807-9AD1-85E370F751E3Q33873095-0DF6D233-05C5-4063-A5D0-9A22F27B0B1CQ33911180-D9689E06-CA8B-4DF1-80AE-F8766403E8F0Q33995172-7EF6AC60-DA29-46A1-A8DB-EE7ED56FE2C6Q34011705-1BF30BD8-6B85-4E55-9202-214FAABA8445Q34031229-0019FC85-E7E4-49E0-B758-76C73C5C51A6Q34258399-D66DC41D-F752-4A33-A802-55A38DC10F25Q34369323-4439F9E7-BC0E-47C3-A46D-E405365956B3Q34430535-A313F296-8953-42F5-90C4-F8F4627149C1Q34483953-48B19DBD-6B6E-4901-BD72-F763E3A4A849Q34503883-628A264D-E4BE-4F8D-9631-4348D549DB24Q34633719-591908C5-AD1C-4547-B5A1-2F002778F498Q34650994-66A240D9-23C2-40B9-8B64-1BF07B4C5BD8Q34785940-BAD7D6C8-F617-44D7-97AD-79E4A63BC166Q34865296-F6FDA5C3-4D3B-470D-A383-C83F4E2EDB8CQ35043675-87AC0A12-08A4-4BFE-9E6E-16ED2F7D978AQ35200455-B1815EF4-DC3C-4D34-838E-DDD837268571Q35200727-817D4BA8-FEAC-4E36-BDA1-D46CB462E19EQ35683412-CEC1E8B5-16BF-4238-9726-37226440DD8EQ35760211-065EF88E-FD21-468E-A2D6-D13D91760931Q35810510-6E6A6428-A7E4-4234-9762-B62F8D18962FQ35817772-0138CCAC-412B-4673-8DC9-29609A3AF2A1Q35828688-0862709E-C9A2-4719-9057-7EEA99432651
P2860
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Intercalated combination of ch ...... andomised, double-blind trial.
@ast
Intercalated combination of ch ...... andomised, double-blind trial.
@en
type
label
Intercalated combination of ch ...... andomised, double-blind trial.
@ast
Intercalated combination of ch ...... andomised, double-blind trial.
@en
prefLabel
Intercalated combination of ch ...... andomised, double-blind trial.
@ast
Intercalated combination of ch ...... andomised, double-blind trial.
@en
P2093
P50
P1433
P1476
Intercalated combination of ch ...... randomised, double-blind trial
@en
P2093
Ashley Cheng
Benjamin Margono
Caicun Zhou
Elisna Syahruddin
Fatima Fuerte
Gee-Chen Chang
Guia Ladrera
Hongming Pan
Hsingjin Eugene Liu
P304
P356
10.1016/S1470-2045(13)70254-7
P577
2013-06-17T00:00:00Z